Alena Cristina Jaime‐Ramirez,Elizabeth L. McMichael,SriVidya Kondadasula,Cassandra C. Skinner,Bethany L. Mundy-Bosse,Eric Luedke,Natalie Jones,Aruna Mani,Julie M. Roda,Volodymyr Karpa,Hong Li,Jilong Li,Saranya Elavazhagan,Krista M. La Perle,Alessandra C. Schmitt,Yanhui Lu,Xiaoli Zhang,Xueliang Pan,Hsaioyin Mao,Melanie E. Davis,David Jarjoura,Jonathan P. Butchar,Ming Poi,Mitch A. Phelps,Susheela Tridandapani,John C. Byrd,Michael A. Caligiuri,Robert J. Lee,William E. Carson

Supplementary Methods and Figure legends from Reducing CD73 Expression by IL1β-Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors

Supplementary Figures 1 - 3 from Reducing CD73 Expression by IL1β-Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplementary Methods, Figure Legends from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression

Supplementary Methods and Figure Legends from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Data from the Mechanism of Anti–PD-L1 Antibody Efficacy Against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 As a Cytolytic Effector

Supplementary Figure Legends from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

Supplementary Figure Legend from CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Supplementary Figure Legends 1-8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure Legends from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Supplementary Figure Legends from Mesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment